Compound 548
Identifiers
- Canonical SMILES:
Fc1ccc(cc1)-n1[nH]c2c3cn[nH]c3nc(-c3cccc(c3)C(F)(F)F)c2c1=O
- InChi:
InChI=1S/C20H11F4N5O/c21-12-4-6-13(7-5-12)29-19(30)15-16(10-2-1-3-11(8-10)20(22,23)24)26-18-14(9-25-27-18)17(15)28-29/h1-9,28H,(H,25,26,27)
- InChiKey:
WYPGGKDHKWVSES-UHFFFAOYSA-N
External links
168318172 |
External search
Bibliography (1)
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 0 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
CD80 / CD28 | 7.00 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 413.09 g/mol | |||
HBA | 6 | |||
HBD | 2 | |||
HBA + HBD | 8 | |||
AlogP | 5.01 | |||
TPSA | 73.91 | |||
RB | 3 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 0 | 0 | 0 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.4780 | 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine | DB08534 | |
0.4719 | Riociguat | DB08931 | |
0.4651 | Decoglurant | DB11923 | |
0.4635 | 6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE | DB07218 | |
0.4591 | Ravoxertinib | DB15281 | |
0.4561 | Vericiguat | DB15456 | |
0.4509 | Dilmapimod | DB12140 | |
0.4488 | MK-0249 | DB11910 | |
0.4458 | Risdiplam | DB15305 | |
0.4425 | Tepotinib | DB15133 | |
0.4375 | ABT-288 | DB15192 | |
0.4369 | ATX-914 | DB12673 | |
0.4360 | (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE | DB07595 | |
0.4346 | N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide | DB08349 | |
0.4340 | 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine | DB07210 |